The Eastern cooperative Oncology Group (ECOG), one of the largest clinical cooperative groups in the country, proposes to continue serving as a Research Base for the 21 applicant programs comprising its Community Clinical Oncology Program (CCOP). The ECOG Research Base has recently undergone significant evolution to improve and expand its cancer prevention and control research capacity. In this proposal, five years of additional support is requested to continue this on-going process of improving and expanding the ECOG Research Base to better serve the needs of the CCOP programs. To meet its on-going responsibilities as a Research Base, ECOG will focus its efforts on the following: 1) Continue to expand and strengthen its cancer prevention, control and treatment research capacity within the CCOP programs and other ECOG participants; 2) Continue to stimulate the development of state-of-the science NCI- approved cancer prevention and control intervention protocols to the CCOP programs and other ECOG participants, including research protocols that specifically target women and underserved populations; 3) Continue to provide the network of community-based physicians and hospitals in ECOG with the necessary services and resources to support state-of-the-science cancer research in the community, including protocol development, patient accrual, data management and quality control, and analytic support; 4) Continue to provide a wide variety of training workshops for the CCOPs, including minority CCOPs, in patient accrual and data management, as well as ECOG, NCI, and FDA procedures and regulations; 5) Continue to provide the CCOPs with the leadership and administrative services described above through the ECOG Operations office and the ECOG Statistical Center, and continue the on-going process of making these key organizational units more responsive to the needs of the CCOP program; 6) Continue to pursue an aggressive program of community-based cancer prevention and control research by being responsive to NCI requests and priority areas in this regard; 7) Continue to fulfill the mandated responsibilities of the Research Base in evaluating and monitoring the activities of the CCOPs through site visits, meetings, progress reports and performance reviews.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA021115-20
Application #
2086914
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1992-09-01
Project End
1995-04-30
Budget Start
1994-08-23
Budget End
1995-04-30
Support Year
20
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Amc Cancer Research Center
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80214
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Sebastian, Sinto; Zhu, Yuan X; Braggio, Esteban et al. (2017) Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood 129:991-1007

Showing the most recent 10 out of 753 publications